Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H1 2017 Summary Wilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 14 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Wilms Tumor Protein - Pipeline Review, H1 2017, outlays comprehensive information on the Wilms Tumor Protein (WT33 or WT1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Wilms Tumor Protein (WT33 or WT1) - Wilms tumor protein is a protein that is encoded by the WT1 gene. It plays an important role in cellular development and cell survival. It plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. It regulates the expression of numerous target genes, including EPO. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 5, 1 and 2 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome, Glioblastoma Multiforme (GBM), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Solid Tumor, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Hematological Tumor, Leukemias, Non-Small Cell Lung Cancer, Pancreatic Cancer, Adrenal Gland Cancer, Fallopian Tube Cancer, Head And Neck Carcinoma, High-Grade Glioma, Lung Cancer, Lymphoma, Malignant Glioma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Ocular Melanoma, Peritoneal Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Small Intestine Cancer, Soft Tissue Sarcoma, Testicular Cancer, Thymic Carcinoma and Thymoma (Thymic Epithelial Tumor). Furthermore, this report also reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1) - The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects - The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein (WT33 or WT1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein (WT33 or WT1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Wilms Tumor Protein (WT33 or WT1) - Overview Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment Assessment by Route of Administration Assessment by Molecule Type Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development GlaxoSmithKline Plc Inovio Pharmaceuticals Inc Otsuka Holdings Co Ltd Sumitomo Dainippon Pharma Co Ltd Vaximm AG Wilms Tumor Protein (WT33 or WT1) - Drug Profiles DSP-7888 - Drug Profile Product Description Mechanism Of Action R&D Progress galinpepimut-S - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-2130579A - Drug Profile Product Description Mechanism Of Action R&D Progress INO-5401 - Drug Profile Product Description Mechanism Of Action R&D Progress OCV-501 - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target WT1 for Leukemia - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target WT1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target WT1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress VXM-06 - Drug Profile Product Description Mechanism Of Action R&D Progress WT-2725 - Drug Profile Product Description Mechanism Of Action R&D Progress WT-4869 - Drug Profile Product Description Mechanism Of Action R&D Progress Wilms Tumor Protein (WT33 or WT1) - Dormant Products Wilms Tumor Protein (WT33 or WT1) - Discontinued Products Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones Featured News & Press Releases May 18, 2017: Sumitomo Dainippon Pharma to Present Clinical Data on WT-2725 at ASCO 2017 Mar 30, 2017: VAXIMM to present preclinical data on VXM06m at AACR Annual Meeting 2017 Mar 01, 2017: SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients Feb 27, 2017: Inovio's SynCon WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy Dec 06, 2016: Boston Biomedical Announces First Clinical Data for Investigational WT1 Cancer Peptide Vaccine, DSP-7888, at ASH Annual Meeting & Exposition Dec 01, 2016: VAXIMM Presents Preclinical Data on VXM-06 at EORTC-NCI-AACR Symposium Nov 04, 2016: Sumitomo Dainippon Pharma Announces the Data of an Investigational WT1 Cancer Peptide Vaccine, DSP-7888 will be Presented at the ASH 2016 Oct 19, 2016: SELLAS Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy OfficeR Oct 13, 2016: SELLAS Life Sciences Announces Positive Interim Phase II Results from its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients Oct 03, 2016: SELLAS Life Sciences Appoints Industry Experts to Support Advancement of Cancer Therapeutics Pipeline Sep 19, 2016: SELLAS Life Sciences Receives FDA Fast Track Designation of Galinpepimut-S for the Treatment of Malignant Pleural Mesothelioma Jun 06, 2016: SELLAS Life Sciences Announces Exciting Results for Galinpepimut-S, the Company's WT1 Vaccine, in Patients with Acute Myeloid Leukemia and Malignant Pleural Mesothelioma, as Presented at the 2016 ASCO Annual Meeting May 24, 2016: SELLAS Life Sciences Announces Upcoming Presentation of Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting May 04, 2016: SELLAS Life Sciences Announces Positive WT1 Cancer Vaccine (galinpepimut-S) Clinical Results at the 13th International Conference of the International Mesothelioma Interest Group (iMig) Apr 29, 2016: SELLAS Life Sciences Group Announces Initiation of Galinpepimut-S (WT1 Cancer Vaccine) Phase 1 Clinical Trial in Combination with PD-1 Checkpoint Inhibitor for Patients with Ovarian Cancer Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by GlaxoSmithKline Plc, H1 2017 Pipeline by Inovio Pharmaceuticals Inc, H1 2017 Pipeline by Otsuka Holdings Co Ltd, H1 2017 Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017 Pipeline by Vaximm AG, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
